Fiscal Year:
2002
Title:
HIGH-THROUGHPUT DNA MICROARRAYS FOR OSTEOBLASTS
Agency:
HHS
Contract:
1R43HD044142-01
Award Amount:
$98,226.00
Abstract:
A quantitative high-throughput gene chip assay, ArrayPlateTM, based on nuclease protection has been developed for drug discovery. We will use this technology to develop an assay that can measure in
a single well of a 96-well microplate, the differentiation of stem cells to
osteoblasts or myoblasts as a model system for stem cell differentiation. This
assay can be used to screen for compounds that initiate differentiation along a
specified pathway.
Our patented method applies nuclease protection protocols to gene chips. This
allows DNA array technology to be used in high throughput - with accuracy and
precision. Briefly, cells are lysed in the presence of nuclease protection
oligonucleotides that hybridize to and protect all targeted mRNA sequences.
After nuclease digestion, oligonucleotides bound stoichiometrically to targeted
sequences are quantified on gene chips, relative to the oligonucleotides as
standards. Hybridization specificity is confirmed within each sample. The
method is sensitive enough to measure genes expressed at very low levels - down
to one mRNA molecule per cell, from 30,000 cells. The cells are grown and
treated in individual wells of a 96-well plate.
Small Business Information at Submission:
NEOGEN, LLC
NEOGEN, LLC BOX 64326, UNIVERSITY OF ARIZONA TUCSON, AZ 85728
EIN/Tax ID:
860897386
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned:
No
Minority-Owned:
No
HUBZone-Owned:
No